Insights

Why is the Mesoblast (ASX:MSB) share price frozen?

The Mesobalst (ASX: MSB) share price won’t be going anywhere today after the company requested a trading halt pending a capital raise.
The post Why is the Mesoblast (ASX:MSB) share price frozen? appeared first on The Motley Fool Australia. –

asx share price trading halt represented by stop sign

Mesoblast Limited (ASX: MSB) shares have been halted in their tracks on Friday. On a day when it is likely fortunate to be missing the action, the Mesoblast share price won’t be going anywhere after the company requested the trading halt prior to market open this morning.

Let’s take a look at why the biotech company requested the pause in trading.

Why did Mesoblast request a trading halt?

Mesoblast shares are on hiatus today as the junior healthcare company prepares to raise capital via a private placement to a “targeted industry investor”.

The Mesoblast share price is expected to remain in a trading halt until such time as the company makes a further announcement or, at the latest, Tuesday next week.

The company did not provide any insights into why it is seeking to raise capital.

Mesoblast share price soars on study results

Earlier this month, the Mesoblast share price surged after the company released promising results from a phase-3 clinical trial.

Prior to the announcement, the stem-cell research company had been conducting a six-year clinical trial on treatment to reduce lower back pain.  

According to Mesoblast, patients who had a single injection of its rexlemestrocel-L reported a reduction in their back pain. These patients, who suffered from inflammatory disc disease, reported no pain for at least two years and were compared to patients treated with a placebo.

Management has advised it intends to meet with the United States Food and Drug Administration to discuss potential approval pathways for rexlemestrocel-L.

How have Mesoblast shares been performing?

Mesoblast describes itself as a world leader in the development of regenerative medicines for inflammatory diseases. 

The company was a favourite among retail investors last year after it announced promising results for its Remestemcel-L (Ryonsil) treatment for COVID-19.

After hitting a six-year peak of $5.50 in September last year, the Mesoblast share price has more than halved. Mesoblast shares crashed from their highs late last year after the company reported a setback to its COVID-19 treatment trial.

Mesoblast cited that changes in the treatment regimens for COVID-19 patients were to blame for the trial’s failure.

Shares in Mesoblast have returned to being one of the most shorted on the ASX, with an 8.8% short interest. 

The Mesoblast share price last traded at $2.46, marking a 6.5% increase for the year to date.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why is the Mesoblast (ASX:MSB) share price frozen? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!